CDK4/6 inhibitors can promote anti-tumor immunity by increasing the production of type III interferons and tumor antigen presentation and suppressing regulatory T cells, through reducing the activity of E2F [36] and mTOR inhibitors are immunosuppressive [37]. Here, MTOR is linked to neoplasm.